Analytical Strategies that Support OSD Formulation: A New Whitepaper from Malvern Instruments
A new whitepaper from Malvern Instruments provides detailed guidance on the analytical technologies that help to accelerate oral solid dosage (OSD) product formulation to a successful conclusion. ‘Analytical techniques with a place in the oral solid dosage formulation toolkit’ reviews the regulatory and QbD framework associated with OSD formulation and demonstrates how Malvern systems can be used to generate the data required.
The goal of formulation is to incorporate an identified drug substance into a successful pharmaceutical product. The regulatory framework for OSD products highlights the need to comprehensively characterize the drug substance and any excipients both individually and when blended to achieve this goal.
In the new whitepaper the potential role of different analytical techniques is discussed with reference to each step of the formulation process. The techniques explored include: laser diffraction particle size analysis, for the control of excipient milling processes and final tablet spray coating; gel permeation/size exclusion chromatography for the characterization of controlled release excipients; and Morphologically Directed Raman Spectroscopy (MDRS) for polymorph detection and assessment of the impact of processing steps on the properties of the drug substance.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.